No Data
No Data
No Data
No Data
No Data
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious
GlobeNewswire19:00
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H'24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
GlobeNewswireMar 27 19:00
Atea Pharmaceuticals: Balancing Promising Prospects With Clinical and Regulatory Risks
TipRanksMar 1 14:07
Earnings Call Summary | Atea Pharmaceuticals(AVIR.US) Q4 2023 Earnings Conference
The following is a summary of the Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript:Financial Performance:Atea Pharmaceuticals reported an increase in R&D expenses for Q4 and full yea
Futu NewsFeb 29 22:18 · Conference Call
Q4 2023 Atea Pharmaceuticals Inc Earnings Call
Yahoo FinanceFeb 29 20:02
Recap: Atea Pharmaceuticals Q4 Earnings
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsAtea Pharmaceuticals b
BenzingaFeb 29 05:35
No Data
No Data